Early data suggest that the 2024-2025 flu shots have effectively lowered rates of flu hospitalization and outpatient visits ...

The Food and Drug Administration (FDA) abruptly canceled a vaccine advisory meeting where members were slated to discuss ...

The U.S. Food and Drug Administration confirmed on Thursday that a meeting of its independent advisory panel to discuss the ...

The influenza vaccine for the 2024/2025 season provided moderate protection against influenza A and strong protection against ...

Flu vaccine makers may face a last-minute scramble to produce enough doses after an FDA advisory committee meeting was ...

So far this season, the vaccine's protection against flu hospitalization was at least 63% for children and at least 41% for adults. These estimates of effectiveness against hospitalization, released ...

“Findings in this report show that vaccination with the 2024–2025 influenza vaccine reduced the likelihood of medically attended influenza and support CDC’s recommendation that all persons aged ≥6 ...

Two long-planned vaccine meetings — one at the US Centers for Disease Control and another at the US Food and Drug ...

The meeting cancellation came one day before the CDC issued its weekly MMWR report, a scientific update on the latest ...

So far, fewer than half of US children and older adults have been vaccinated during this year’s high-severity flu season.

Lab tests suggest a strain of the flu virus circulating this season may not be "well-recognized" by the flu vaccine.

The FDA canceled a meeting of vaccine advisors scheduled for next month to decide the composition of next season's influenza ...